TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner

American Journal of Translational Research

Volumn 8, Issue 9, 2016, Pages 3848-3860

  Yang, Bin ^a   Yan, Ping ^a   Gong, Hui ^a   Zuo, Lin ^a   Shi, Ying ^a   Guo, Jian ^b   Guo, Rui ^a   Xie, Jun ^a   Li, Bao ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b Senboll Biotechnology Inc   (Canada)

Author keywords

Apoptosis; Cardiac ischemia reperfusion injury; Cardiomyocytes; Signaling pathway; TWEAK

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CRYTOTANSHINONE; FIBROBLAST GROWTH FACTOR 14; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR DERIVATIVE; TWEAK; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HEART CELL CULTURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUNEL ASSAY; WESTERN BLOTTING;

EID: 84988811694     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M and Shalhoub J. Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation 2016; 133: 1916-1926.
2. Hai JJ, Chan PH, Huang D, Ho MH, Ho CW, Cheung E, Lau CP, Tse HF and Siu CW. Clinical Characteristics, Management, and Outcomes of Hospitalized Heart Failure in a Chinese Population-The Hong Kong Heart Failure Registry. J Card Fail 2016; 22: 600-8.
3. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994; 343: 311-322.
4. Weintraub WS, Grau-Sepulveda MV, Weiss JM, O’Brien SM, Peterson ED, Kolm P, Zhang Z, Klein LW, Shaw RE, McKay C, Ritzenthaler LL, Popma JJ, Messenger JC, Shahian DM, Grover FL, Mayer JE, Shewan CM, Garratt KN, Moussa ID, Dangas GD and Edwards FH. Comparative effectiveness of revascularization strategies. N Engl J Med 2012; 366: 1467-1476.
5. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP and Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352: 2174-2183.
6. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ and Schwaiger M. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343: 385-391.
7. Bulluck H, Yellon DM and Hausenloy DJ. Reducing myocardial infarct size: challenges and future opportunities. Heart 2016; 102: 341-348.
8. Gottlieb RA, Burleson KO, Kloner RA, Babior BM and Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94: 1621-1628.
9. Orogo AM and Gustafsson AB. Cell death in the myocardium: my heart won’t go on. IUBMB Life 2013; 65: 651-656.
10. Thapalia BA, Zhou Z and Lin X. Autophagy, a process within reperfusion injury: an update. Int J Clin Exp Pathol 2014; 7: 8322-8341.
11. Linkermann A, Hackl MJ, Kunzendorf U, Walczak H, Krautwald S and Jevnikar AM. Necroptosis in immunity and ischemia-reperfusion injury. Am J Transplant 2013; 13: 2797-2804.
12. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, Torre T, Siclari F, Moccetti T and Vassalli G. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 2014; 103: 530-541.
13. Bergmann MW, Rechner C, Freund C, Baurand A, El Jamali A and Dietz R. Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin. J Mol Cell Cardiol 2004; 37: 681-690.
14. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I and Browning JL. TWEAK, a new secreted ligand in the tumor ne- crosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401-32410.
15. Blanco-Colio LM. TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. Front Immunol 2014; 5: 3.
16. Novoyatleva T, Sajjad A and Engel FB. TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. Front Immunol 2014; 5: 50.
17. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA and Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-846.
18. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-425.
19. Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A and Ruiz-Ortega M. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J Pathol 2013; 231: 480-494.
20. Pachel C, Mathes D, Bayer B, Dienesch C, Wangorsch G, Heitzmann W, Lang I, Ardehali H, Ertl G, Dandekar T, Wajant H and Frantz S. Exogenous administration of a recombinant variant of TWEAK impairs healing after myocardial infarction by aggravation of inflammation. PLoS One 2013; 8: e78938.
21. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA and Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455-8459.
22. Ren MY and Sui SJ. The role of TWEAK/Fn14 in cardiac remodeling. Mol Biol Rep 2012; 39: 9971-9977.
23. Novoyatleva T, Schymura Y, Janssen W, Strobl F, Swiercz JM, Patra C, Posern G, Wietelmann A, Zheng TS, Schermuly RT and Engel FB. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol 2013; 108: 325.
24. Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S and Covic A. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol 2013; 14: 144.
25. Shi J, Jiang B, Qiu Y, Guan J, Jain M, Cao X, Bauer M, Su L, Burkly LC, Leone TC, Kelly DP and Liao R. PGC1alpha plays a critical role in TWEAK-induced cardiac dysfunction. PLoS One 2013; 8: e54054.
26. Richter B, Rychli K, Hohensinner PJ, Berger R, Mortl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hulsmann M and Niessner A. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 2010; 213: 545-548.
27. Mustonen E, Sakkinen H, Tokola H, Isopoussu E, Aro J, Leskinen H, Ruskoaho H and Rysa J. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) 2010; 199: 11-22.
28. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS, Liao R and Burkly LC. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009; 119: 2058-2068.
29. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM and Winkles JA. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-33176.
30. Ikner A and Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem 2011; 286: 21546-21554.
31. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K and Yagita H. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003; 170: 341-348.
32. Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE and Niessen HW. Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 2002; 55: 801-811.
33. Yan P, Chen KJ, Wu J, Sun L, Sung HW, Weisel RD, Xie J and Li RK. The use of MMP2 anti-body-conjugated cationic microbubble to target the ischemic myocardium, enhance Timp3 gene transfection and improve cardiac function. Biomaterials 2014; 35: 1063-1073.
34. Yan P, Gong H, Zhai X, Feng Y, Wu J, He S, Guo J, Wang X, Guo R, Xie J and Li RK. Decreasing CNPY2 Expression Diminishes Colorectal Tumor Growth and Development through Activation of p53 Pathway. Am J Pathol 2016; 186: 1015-1024.
35. Whelan RS, Kaplinskiy V and Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010; 72: 19-44.
36. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC and Anversa P. Apop- tosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141.
37. Gottlieb RA. Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther 2011; 16: 233-238.
38. Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, Frede S, Hartung T, Vinten-Johansen J, Youker KA, Entman ML, Er-bel R and Heusch G. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol 2002; 34: 51-62.
39. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ and Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-635.
40. Chapman MS, Wu L, Amatucci A, Ho SN and Michaelson JS. TWEAK signals through JAK-STAT to induce tumor cell apoptosis. Cytokine 2013; 61: 210-217.
41. Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA and Frey N. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 2010; 105: 301-313.
42. Zhang Z, Fang Y, Wang Q, Sun Y, Xiong C, Cao L, Wang B, Bao N and Zhao J. Tumor necrosis factor-like weak inducer of apoptosis regulates particle-induced inflammatory osteolysis via the p38 mitogen-activated protein kinase signaling pathway. Mol Med Rep 2015; 12: 1499-1505.
43. Zhi-Chun L, Qiao-Ling Z, Zhi-Qin L, Xiao-Zhao L, Xiao-xia Z and Rong T. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis. Inflammation 2012; 35: 935-943.
44. Burkly LC. Regulation of Tissue Responses: The TWEAK/Fn14 Pathway and Other TNF/ TNFR Superfamily Members That Activate Non-Canonical NFkappaB Signaling. Front Immunol 2015; 6: 92.
45. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA and Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005; 280: 3483-3492.
46. Valen G, Yan ZQ and Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001; 38: 307-314.
47. Wilhide ME, Tranter M, Ren X, Chen J, Sartor MA, Medvedovic M and Jones WK. Identification of a NF-kappaB cardioprotective gene program: NF-kappaB regulation of Hsp70.1 contributes to cardioprotection after permanent coronary occlusion. J Mol Cell Cardiol 2011; 51: 82-89.
48. Riggins RB, Zwart A, Nehra R and Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005; 4: 33-41.
49. Tong Y, Zhu W, Huang X, You L, Han X, Yang C and Qian W. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep 2014; 31: 1581-1588.
50. Ghigo A and Li M. Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. Front Pharmacol 2015; 6: 169.
51. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G and Schulz R. The myocardial JAK/ STAT pathway: from protection to failure. Pharmacol Ther 2008; 120: 172-185.
52. Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK and Siddiqui MA. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 2001; 104: 325-329.
53. Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F and Rahim F. STATs: An Old Story, Yet Mesmerizing. Cell J 2015; 17: 395-411.
54. Villarino AV, Kanno Y, Ferdinand JR and O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 2015; 194: 21-27.
55. Li W, Saud SM, Young MR, Colburn NH and Hua B. Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro. Mol Cell Biochem 2015; 406: 63-73.
56. Kobayashi A, Tanizaki Y, Kimura A, Ishida Y, No-saka M, Toujima S, Kuninaka Y, Minami S, Ino K and Kondo T. AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer. Eur J Pharmacol 2015; 766: 63-75.
57. Brown DI and Griendling KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 2015; 116: 531-549.
58. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ and Sugden PH. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996; 79: 162-173.
59. Yokota T and Wang Y. p38 MAP kinases in the heart. Gene 2016; 575: 369-376.
60. Lin KH, Kuo WW, Jiang AZ, Pai P, Lin JY, Chen WK, Day CH, Shen CY, Padma VV and Huang CY. Tetramethylpyrazine Ameliorated Hypoxia-Induced Myocardial Cell Apoptosis via HIF-1al-pha/JNK/p38 and IGFBP3/BNIP3 Inhibition to Upregulate PI3K/Akt Survival Signaling. Cell Physiol Biochem 2015; 36: 334-344.
61. Hreniuk D, Garay M, Gaarde W, Monia BP, McKay RA and Cioffi CL. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol 2001; 59: 867-874.
62. Pac-Soo CK, Mathew H and Ma D. Ischaemic conditioning strategies reduce ischaemia/reperfusion-induced organ injury. Br J Anaesth 2015; 114: 204-216.
63. Xue Y, Xie N, Lin Y, Xu J, Han Y, Wang S, Jiang H and Chi Z. Role of PI3K/Akt in diazoxide preconditioning against rat hippocampal neuronal death in pilocarpine-induced seizures. Brain Res 2011; 1383: 135-140.
64. Jang HS, Kim J, Kim KY, Kim JI, Cho MH and Park KM. Previous ischemia and reperfusion injury results in resistance of the kidney against subsequent ischemia and reperfusion insult in mice; a role for the Akt signal pathway. Nephrol Dial Transplant 2012; 27: 3762-3770.